Dual antiplatelet therapy (DAPT) for 1 to 3 months after complex percutaneous intervention followed by P2Y12 inhibitor monotherapy showed a similar rate of death and ischemic events and reduced major bleeding compared to standard DAPT, regardless of whether the patients underwent complex or non-complex percutaneous coronary intervention (PCI), according to a new pooled analysis of five randomized control trials (RCTs).